A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib
文献类型：期刊论文
| 作者 | Zhong, Nanzhe4; Yu, Dong3; Yang, Minglei4; Lu, Xingyi2; Zhang, Qiangzu2; Wei, Wei4; Jiao, Jian4; Yang, Xinghai4; Zhu, Zhi1; Chen, Su4 |
| 刊名 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
 |
| 出版日期 | 2024-02-19 |
| 卷号 | 150期号:2页码:9 |
| 关键词 | Chordoma Palbociclib Genomic features Drug resistance |
| ISSN号 | 0171-5216 |
| DOI | 10.1007/s00432-023-05560-x |
| 英文摘要 | PurposeThere is no approved targeted therapy for chordoma at present. Although several preclinical studies have implied the potential applicability of CDK4/6 inhibitor for this rare tumor, no clinical evidence has been documented so far. The purpose of this study was to elucidate the therapeutic efficacy of CDK4/6 inhibitor for chordoma.MethodsThe next generation sequencing (as for whole-exome sequencing, WES assay) and immunohistochemical (IHC) staining of the chordoma tissue from a patient with an advanced lesion were performed before treatment. Then, the patient was treated with Palbociclib for 4 months until progression occurred in the 5th month. Surgical resection was implemented and the tumor tissue was obtained postoperatively for assessment of molecular alterations.ResultsMolecular features of the tumor before medical treatment suggested applicability of CDK4/6 inhibitor and the patient showed partial response (PR) according to Choi Criteria after 4 months treating with Palbociclib until progression occurred. Then, a drastic molecular alteration of the tumor as represented by emergence of dramatic E2F amplification, which is known to induce CDK4/6 independent cell-cycle entry and progression after treatment, was detected. The findings in this patient demonstrated tumor evolution under drug pressure.ConclusionThe findings of the present study suggest the feasibility of Palbociclib for the clinical treatment of chordoma, and imply the necessity of combination therapies rather single drug administration due to the quick resistance of the tumor to Palbociclib treatment. |
| 资助项目 | The National Natural Science Fund Project of China[82141105] ; The National Natural Science Fund Project of China[81902731] ; National Natural Science Fund Project of China |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:001163925200003 |
| 出版者 | SPRINGER |
| 源URL | [http://119.78.100.204/handle/2XEOYT63/38862]  |
| 专题 | 中国科学院计算技术研究所期刊论文_英文 |
| 通讯作者 | Chen, Su; Xiao, Jianru |
| 作者单位 | 1.Naval Med Univ, Changzheng Hosp, Dept Pathol, Shanghai, Peoples R China 2.Chinese Acad Sci, State Key Lab Comp Architecture, Inst Comp Technol, Beijing, Peoples R China 3.Naval Med Univ, Ctr Translat Med, Shanghai 200433, Peoples R China 4.Naval Med Univ, Shanghai Changzheng Hosp, Dept Orthoped Oncol, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhong, Nanzhe,Yu, Dong,Yang, Minglei,et al. A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,2024,150(2):9. |
| APA | Zhong, Nanzhe.,Yu, Dong.,Yang, Minglei.,Lu, Xingyi.,Zhang, Qiangzu.,...&Xiao, Jianru.(2024).A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,150(2),9. |
| MLA | Zhong, Nanzhe,et al."A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib".JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 150.2(2024):9. |
入库方式： OAI收割
来源：计算技术研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。